20th Aug 2008 11:27
GENETHERA POTENTIAL OFFER FOR OXFORD BIOMEDICA
WHEAT RIDGE, CO, August 20, 2008 - Further to the announcement released by Oxford Biomedica Plc on August 15, 2008, GeneThera, Inc. (Pink Sheets: GTHR), would like to announce that is currently considering its options in respect of a potential acquisition of Oxford Biomedica Plc. Any offer, if made, will be a securities exchange offer. There can be no certainty that an offer will be made. A further announcement will be made in due course.
"Dealing Disclosure Requirements"
Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any person is,
or becomes, "interested" (directly or indirectly) in 1% or more of any class of
"relevant securities" of GeneThera, Inc., Oxford Biomedica Plc., all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of GeneThera, Inc., Oxford Biomedica Plc., they will be deemed to be a single person for the purpose of Rule 8.3.
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of
GeneThera, Inc., Oxford Biomedica Plc., or by any of their respective "associates", must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction. A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk.
"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of securities. In
particular, a person will be treated as having an "interest" by virtue of the ownership
or control of securities, or by virtue of any option in respect of, or derivative
referenced to, securities. Terms in quotation marks are defined in the Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel." NB1 Where it has been announced that an offer or possible offer is, or is likely to be, solely in cash, there is no requirement to disclose dealings in relevant securities of GeneThera, Inc. (see Note 2 on Rule 8 of the Code).
ABOUT GENETHERA, INC.:
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression system, GES, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E. Coli 0157:H7 and Johne's Disease, diseases affecting cattle worldwide.
___________________________
GeneThera, Inc.
Dr. Tony Milici, 303-463-6371
http://www.genethera.net
JR Dopkin & Associates
[email protected]; 516-884-3200
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as ``intends,'' ``believes,'' and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Related Shares:
Oxford Biomedica